Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.

Cheng G, Sun X, Wang J, Xiao G, Wang X, Fan X, Zu L, Hao M, Qu Q, Mao Y, Xue Y, Wang J.

Cancer Res. 2014 Feb 1;74(3):862-72. doi: 10.1158/0008-5472.CAN-13-2420. Epub 2013 Dec 2.

2.

Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.

Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, Kim DG.

Hepatology. 2013 Oct;58(4):1349-61. doi: 10.1002/hep.26467. Epub 2013 Aug 7.

PMID:
23696034
3.

Lipocalin 2 promotes breast cancer progression.

Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8. doi: 10.1073/pnas.0810617106. Epub 2009 Feb 23.

4.

Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.

Wu CH, Ko JL, Chen SC, Lin YW, Han CP, Yang TY, Chien MH, Wang PH.

Gynecol Oncol. 2014 Feb;132(2):474-82. doi: 10.1016/j.ygyno.2013.11.032. Epub 2013 Dec 4.

PMID:
24316309
5.

Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.

Gaudineau B, Fougère M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S.

J Cell Sci. 2012 Oct 1;125(Pt 19):4475-86. doi: 10.1242/jcs.099879. Epub 2012 Jul 5.

6.

Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.

Ding G, Fang J, Tong S, Qu L, Jiang H, Ding Q, Liu J.

Prostate. 2015 Jun 15;75(9):957-68. doi: 10.1002/pros.22978. Epub 2015 Feb 25.

PMID:
25728945
7.

The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Foveau B, Boulay G, Pinte S, Van Rechem C, Rood BR, Leprince D.

J Biol Chem. 2012 Feb 17;287(8):5366-78. doi: 10.1074/jbc.M111.329466. Epub 2011 Dec 19.

8.

ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.

Mahadevan NR, Rodvold J, Almanza G, Pérez AF, Wheeler MC, Zanetti M.

BMC Cancer. 2011 Jun 7;11:229. doi: 10.1186/1471-2407-11-229.

9.

Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.

Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR, Goydos JS, Gorski DH.

PLoS One. 2014 Jan 3;9(1):e81126. doi: 10.1371/journal.pone.0081126. eCollection 2014.

10.

Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.

Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB.

Cancer Res. 2009 Nov 15;69(22):8579-84. doi: 10.1158/0008-5472.CAN-09-1934. Epub 2009 Nov 3.

11.

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.

Blanchard Z, Paul BT, Craft B, ElShamy WM.

Breast Cancer Res. 2015 Jan 13;17:5. doi: 10.1186/s13058-014-0512-9.

12.

Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.

Zhao C, Qiao Y, Jonsson P, Wang J, Xu L, Rouhi P, Sinha I, Cao Y, Williams C, Dahlman-Wright K.

Cancer Res. 2014 Jul 15;74(14):3983-94. doi: 10.1158/0008-5472.CAN-13-3396. Epub 2014 May 15.

13.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

14.

Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade.

Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT.

Mol Pharm. 2014 Mar 3;11(3):755-65. doi: 10.1021/mp4004699. Epub 2014 Feb 12.

15.

Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.

Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu J, Jin W.

Oncotarget. 2015 Jun 30;6(18):16352-65.

16.

NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.

Fougère M, Gaudineau B, Barbier J, Guaddachi F, Feugeas JP, Auboeuf D, Jauliac S.

Oncogene. 2010 Apr 15;29(15):2292-301. doi: 10.1038/onc.2009.499. Epub 2010 Jan 25.

PMID:
20101218
17.

Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.

Chung IH, Chen CY, Lin YH, Chi HC, Huang YH, Tai PJ, Liao CJ, Tsai CY, Lin SL, Wu MH, Chen CY, Lin KH.

Oncotarget. 2015 Jun 20;6(17):15050-64.

18.

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.

19.

C/EBP ζ targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells.

Wang L, Li H, Wang J, Gao W, Lin Y, Jin W, Chang G, Wang R, Li Q, Ma L, Pang T.

Biochim Biophys Acta. 2011 Oct;1813(10):1803-13. doi: 10.1016/j.bbamcr.2011.06.010. Epub 2011 Jun 30.

20.

Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1.

Mir SU, Jin L, Craven RJ.

J Biol Chem. 2012 Apr 27;287(18):14494-501. doi: 10.1074/jbc.M111.324921. Epub 2012 Mar 14.

Items per page

Supplemental Content

Write to the Help Desk